Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.00
Bid: 13.50
Ask: 14.50
Change: 0.00 (0.00%)
Spread: 1.00 (7.407%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 14.00
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

1 Aug 2005 07:01

Angle PLC01 August 2005 For Immediate Release 1 August 2005 ANGLE plc ("ANGLE" or the "Company") Formation of Executive Management Board and Board Change ANGLE plc, the venture management and consulting company specialising in thecommercialisation of technology and the development of technology-based industryannounces the formation of an Executive Management Board which will reportdirectly to the ANGLE plc Board. In recognition of the Company's recent successes, rapid expansion and futureprospects across the United Kingdom, United States and the Middle East, ANGLEhas strengthened its management structure and promoted Stephen Bates, currentlyDirector of UK Ventures, to UK Chief Executive. Responsibility for HR,marketing, IT and operations will now be devolved from the Board to regionalchief executives ensuring full responsibility for all activities in theirrespective regions. With immediate effect, the Executive Management Board will consist of Group CEO,Andrew Newland and Finance Director, Ian Griffiths, together with: Stephen Bates, UK Chief Executive Stephen Bates has an MA in engineering, and an MBA. Following 10 years withinthe product development industry his career has taken him to ScientificGenerics, Arthur D. Little and Marks & Spencer prior to joining ANGLE in 2004.Dr Gary Evans, US Chief Executive Gary Evans has a BSc in Chemistry, a PhD in Physical Chemistry, and a Diploma inManagement Science and was Visiting Professor in Innovation Management at theRobert Gordon University, Aberdeen. Following a career with Cambridge LifeSciences and then Scottish Enterprise, Dr. Evans joined ANGLE in 1997. Dr Eulian Roberts, Middle East Chief Executive Eulian Roberts has a BSc in Microbiology, a PhD in Molecular Biology and an MBA.He gained three years' post-doctoral experience and then joined ScottishEnterprise. He then became chief executive of the Stirling University InnovationPark, managing director of Coventry University Enterprises Limited and adirector of the UK Science Park Association. Dr Roberts joined ANGLE in 1998. As a result of these changes, Dawson Buck will be stepping down from hisposition as Deputy Chief Executive, with immediate effect. He remains a directorof ANGLE's venture companies, Corpora plc and Provexis plc. Commenting on the new organisational structure, Group CEO, Andrew Newland, said: "The formation of an Executive Management Board establishes a clear managementstructure and accountability by region which will improve the efficiency andintegration of our Consulting & Management and Ventures operations, streamlineoverheads and facilitate our continuing rapid growth. The new management structure gives us the platform we need to grow the businesssubstantially. I am delighted to have such high calibre individuals within theExecutive Management Board. I would also like to put on record my thanks to Dawson Buck for all hiscontributions to the ANGLE Board over the last five years." For further information ANGLE plcAndrew Newland, Chief Executive Tel: +44 (0)1483 295830 Buchanan Communications Tel: +44 (0)20 7466 5000Richard Darby, Suzanne Brocks, James Strong Notes to Editors Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE is listed on AIM (AGL.L); further information can be found onwww.ANGLEplc.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
1st Jul 20147:00 amRNSNotification of Preliminary Results
29th Apr 20144:30 pmRNSHoldings in Company
8th Apr 20147:00 amRNSIntellectual Property Update
24th Mar 20147:00 amRNSAppointment of Scientific Adviser
17th Mar 20147:00 amRNSParsortix FDA Submission
24th Feb 20147:00 amRNSUse of Parsortix System with Liver Cancer Patients
18th Feb 20147:00 amRNSParsortix Launch at Circulate Conference in Berlin
30th Jan 20147:00 amRNSInterim Results
13th Jan 20147:00 amRNSCambridge Parsortix Laboratory
10th Jan 20147:00 amRNSNotification of Interim Results and Webcast
7th Jan 20147:00 amRNSAppointment of Scientific Adviser
17th Dec 20137:00 amRNSCE Mark Authorisation
13th Dec 20137:00 amRNSRaises £6.2m from Sale of Geomerics
31st Oct 20133:31 pmRNSResult of 2013 Annual General Meeting
9th Oct 20137:00 amRNSAnnual Report and Accounts and Notice of AGM
31st Jul 20137:00 amRNSPreliminary Results
25th Jul 20137:00 amRNSPositive Evaluation of Parsortix System
19th Jul 20137:00 amRNSNotification of Preliminary Results and Webcast
8th Jul 20137:00 amRNSParsortix Colorectal Cancer Validation
29th May 20137:00 amRNSDirector's Share Transfer
28th May 20137:00 amRNSParsortix Manufacturer Appointed
13th May 20137:00 amRNSPARSORTIX CELL HARVESTING
7th May 20137:00 amRNSParsortix Regulatory Approval Update
28th Feb 20137:00 amRNSParsortix Research Product Launch
15th Feb 201310:56 amRNSDirector's share transfer
31st Jan 20137:01 amRNSFundraising and Director's Dealings
31st Jan 20137:00 amRNSInterim Results
16th Jan 20137:00 amRNSNotification of Interim Results and Webcast
14th Jan 20137:00 amRNSParsortix Cell Recovery
7th Jan 20137:00 amRNSAppointment of NED
18th Dec 20127:00 amRNSParsortix Released to Research Partners
10th Dec 20127:00 amRNSBUSINESS UPDATE
18th Oct 20127:00 amRNSAppointment of Scientific Advisers
17th Oct 20123:45 pmRNSHolding(s) in the Company
11th Oct 20123:39 pmRNSResult of 2012 Annual General Meeting
3rd Sep 20127:00 amRNSIncreased Fundraising
1st Aug 20127:00 amRNSIncreased Fundraising
26th Jul 20127:01 amRNSFundraising
26th Jul 20127:00 amRNSPreliminary Results
24th Jul 20127:00 amRNSNotice of Preliminary Results and Conference Call
27th Jun 20127:00 amRNSOffer Unconditional for Novocellus' Partner Origio
7th Jun 20127:00 amRNSUpdate Re Novocellus' Partner ORIGIO A/S
16th May 20127:00 amRNSGeomerics Milestone Payment
30th Apr 20127:00 amRNSParsortix Design Breakthrough
26th Apr 20127:00 amRNSLaunches New Corporate Website
23rd Apr 20127:00 amRNSParsortix Update for Breast Cancer
17th Apr 20127:00 amRNSParsortix Validation for Ovarian Cancer
11th Apr 20127:00 amRNSNovocellus Embryosure® Trial Started
26th Mar 20127:00 amRNSGeomerics Update
15th Mar 20127:00 amRNSParsortix Validation for Colon Cancer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.